BackTable Vascular & Interventional

How do you safely combine locoregional and systemic therapies to treat hepatocellular carcinoma (HCC) when traditional guidelines suggest your hands are tied? In this episode of the 2026 HCC Creator Weekend™, medical oncologist Dr. Lingling Du (Ochsner Health) and interventional radiologist Dr. Beau Toskich (Mayo Clinic Florida) join Dr. Tyler Sandow to break down patient selection, timing strategies, and the practical application of clinical trial outcomes when integrating Y90 radioembolization and immunotherapy in HCC management.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by an educational grant from Sirtex and Boston Scientific.

---

Timestamps

00:00 - Introduction
01:48 - Two HCC Cases
03:31 - Disease Progression on Combination Therapy
07:05 - Alternatives After Immunotherapy Failure
09:09 - Salvage with Ablative Y90
13:41 - Mechanism of Immunotherapy
15:43 - EMERALD-1 and LEAP-012
20:52 - Adverse Events with Combination Therapy
27:21 - Treatment Timing and Sequencing
28:48 - Case: Borderline BCLC B
33:48 - Case: BCLC C with Portal Vein Thrombus
37:06 - Raising the Survival Tail
40:11 - Final Thoughts and Closing Remarks

---

More about this episode

The physicians highlight how selective local treatment can achieve complete responses and salvage cases with aggressive disease. They emphasize that treatment based on anatomical and biological phenotype may yield better results than strictly adhering to rigid staging categories, while acknowledging the challenges of managing microscopic disease and unpredictable long-term tumor behavior. Dr. Du and Dr. Toskich also note that selecting the right combination regimens requires balancing aggressive tumor kinetics against the patient’s baseline liver function, pointing out that well-tolerated regimens like STRIDE are often easier to pair with Y90 than checkpoint or VEGFR inhibitors that alter tumor blood flow. While recent TACE-immunotherapy trials (EMERALD-1 and LEAP-012) may be confounded by patient heterogeneity, the physicians observe that a distinct subset of patients achieves durable, long-term remission, effectively raising the survival tail for an otherwise incurable population. Ultimately, they conclude that cross-specialty education and leaning into the expert intuition of a multidisciplinary team are essential for securing the best outcomes for patients with intermediate and advanced HCC.

---

Resources

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)
https://clinicaltrials.gov/study/NCT03298451

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave150)
https://clinicaltrials.gov/study/NCT03434379

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
https://doi.org/10.1016/S0140-6736(25)00403-9

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
https://doi.org/10.1016/S0140-6736(24)02551-0

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
https://doi.org/10.1016/S0140-6736(24)02575-3

---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

How will expeditionary IR adapt and advance to meet the challenges of the next generation of combat operations? In this episode of the Backtable Podcast, host Dr. Ally Baheti speaks with Air Force IR physicians Dr. John Pavlus and Dr. Jonathon Schutt about the realities of expeditionary interventional radiology (EIR) in military and disaster settings. They discuss how EIR brings damage-control and emergency IR principles to deployments, humanitarian missions, and extreme environments, where resources are limited and teamwork is essential.

---

Get the BackTable app
https://www.backtable.com/app

---

Timestamps

00:00 - Introduction
03:53 - Origins and Early Pushback
06:31 - Roles of Care
09:04 - Trauma vs Elective
12:09 - Staffing and Training Barriers
22:17 - Future Tech: AI and Robotics
29:24 - Why It Matters in War
35:00 - Teamwork Trust and 60 Minutes
39:20 - Military Culture
41:18 - Wrap Up and Thanks

---

More about this episode

The conversation explores the military’s “roles of care,” from stateside hospitals to front-line deployments, and examines how limited IR staffing and siloed services present barriers to readiness. Drs. Pavlus and Schutt emphasize the importance of close integration with trauma surgery, anesthesia, and other team members, and highlight trauma-focused endovascular care and ultrasound-guided procedures that work with minimal equipment. The episode also looks at future directions for expeditionary IR, including new training models, data systems, and advances in AI and robotics that may one day enable remote intervention in combat and disaster zones.

---

Resources

Expeditionary Endovascular Trauma Care as a Core Capability for Future Large-Scale Conflicts
https://pubmed.ncbi.nlm.nih.gov/41894613/

---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

What do you do when Y-90 doesn’t deliver the results you expected? In this episode of the 2026 HCC Creator Weekend™, host Dr. Tyler Sandow is joined by Drs. Beau Toskich and Juan Gimenez to discuss the technical challenges and troubleshooting strategies that can make or break a Y-90 radioembolization case. Together, they explore innovative approaches like the PREDATr technique, share tips for reducing complications, and offer guidance on optimizing outcomes for patients with complex liver tumors.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by an educational grant from Sirtex and Boston Scientific.

---

Timestamps

00:00 - Introduction
04:24 - Treatment Nonresponse Troubleshooting
06:12 - Navigating Y90 Through Replaced Arteries
09:09 - Mitigating Vasospasm in Embolization
13:31 - What is ‘PREDATr’?
21:12 - Dual Balloon Microcatheter System
23:37 - Gelfoam Techniques and Application
26:06 - Embolization Agents Preferences
36:16 - Concerns with Cystic Artery Treatment and Biliary Stents
42:15 - Prophylactic Antibiotics
44:29 - Utilizing High Lung Shunts
49:28 - Wrap Up and Credits

---

More about this episode

The conversation begins with case-based examples of HCC radioembolization, focusing on how to assess treatment response and troubleshoot nonresponsive cases. They discuss how to interpret SPECT findings, identify missed tumor supply with cone-beam CT, and overcome obstacles such as vasospasm, extrahepatic feeders, and challenging arterial anatomy. They introduce the PREDATr technique (proximal radioembolization enabled by distal angiozone truncation) and explain how tools like gelfoam, balloons, and retrievable coils can preserve healthy liver tissue and improve microsphere delivery. The episode also addresses managing biliary stents, using antibiotic prophylaxis, and strategies for handling high lung shunts, making it a practical resource for anyone navigating the complexities of Y-90 treatment.

---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

Are new technologies and teamwork the key to better fibroid treatment? In this episode of the BackTable Podcast, Drs. Francis Kang and Neil Resnick join host Dr. Chris Beck to share how multidisciplinary treatment planning is reshaping uterine fibroid management, from patient selection and referral patterns to procedural techniques that improve outcomes.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by
TriSalus Life Sciences
https://trinavinfusion.com/

---

Timestamps
00:00 - Introduction
06:18 - Multidisciplinary Care of Fibroids
15:45 - Treatment Decisions
21:56 - Managing Asymptomatic Fibroids
25:43 - Collaborative vs. Competitive Practices
30:01 - UFE Procedure Approaches
34:32 - Comparing Embolic Sizes and Amounts
37:44 - Changes in Speed Using TriNav Catheters
40:53 - Tactile Feedback at Stasis
42:28 - Embolization Target Regions
44:45 - Encountering and Troubleshooting Collaterals
47:30 - Post-Op Pain Regiments
57:28 - Wrap Up

---

More about this episode
The conversation begins with the importance of strong partnerships with OBGYN colleagues and how multidisciplinary planning leads to better outcomes for patients. They explore patient selection and education, especially for those considering surgical versus minimally invasive treatment options. Drs. Kang and Resnick compare procedural approaches, including when to use femoral versus transradial access, nerve blocks, and embolic particle selection. They also discuss strategies to achieve optimal embolization endpoints and practical tips for handling collateral vessels, avoiding non-target embolization, and managing post-procedural pain and recovery. The episode concludes with a look at newer technologies like the TriNav Catheter and its impact on embolization speed, operator confidence, and early imaging outcomes.
---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app

How is Y90 radioembolization rewriting the rules for managing large HCC tumors and creating new curative-intent therapeutic pathways where palliation was once deemed the only option? In this episode of the 2026 HCC Creator Weekend™, interventional radiologists Dr. Chris Malone (WashU), Dr. Tyler Sandow (Ochsner Health), and Dr. Beau Toskich (Mayo Clinic Florida) join host Dr. Zach Berman for a case-based discussion on advanced dosimetric strategies and embolization approaches for large and complex HCC lesions.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by an educational grant from Boston Scientific.

---

Timestamps

00:00 - Introduction
01:59 - Case 1: Ablative Dosing to Solitary Tumor
04:38 - Post-Treatment Residual Arterial Enhancement
07:35 - Case 2: Tumor with Multiple Feeding Arteries
10:02 - Role of Combination with Immunotherapy
13:01 - Case 3: Large Caudate Tumor
16:03 - Approach to Extrahepatic Arterial Supply
19:14 - Case 4: Tumor Adjacent to Viscera
21:32 - Does Microsphere Count Matter?
24:10 - Case 5: Radioembolization in HCC Downstaging
28:18 - Dosing Paradigms for Large Tumors
33:06 - Case 6: Pressure-Augmented Delivery
35:16 - Case 7: Multifocal Disease and Satellite Lesions
37:47 - Palliative Dosimetry vs. Radiation Lobectomy
40:11 - Significance of Complete Pathonecrosis
43:25 - Closing Remarks

---

More about this episode
The physicians discuss systematic approaches to patient selection, the nuances of MIRD single-compartment versus multi-compartment dosing, and the critical role of precise mapping and particle dynamics in optimizing treatment for heterogeneous tumors. The panel also examines how to navigate the risks and situational challenges of delivering high radiation doses to large central and multifocal tumors. They address practical concerns such as responding to post-treatment imaging changes, managing long-term risks like biliary strictures, and ensuring the safety of treating disease near mobile viscera. The specialists highlight the power of Y90 in successful downstaging, citing evidence of its superior potential to achieve complete pathological necrosis (CPN) at explant when compared with other modalities. Ultimately, they advocate for a bold, collaborative approach within the multidisciplinary tumor board, encouraging providers to employ combination therapies and advanced technologies to optimize patient outcomes and expand the boundaries of curable HCC.

---

Resources

Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
https://doi.org/10.1002/hep.31819

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)
https://clinicaltrials.gov/study/NCT06040099

TheraSphere With Durvalumab and Tremelimumab for HCC (ROWAN)
https://clinicaltrials.gov/study/NCT05063565

Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
https://doi.org/10.1016/S2468-1253(20)30290-9

Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium
https://doi.org/10.1053/j.gastro.2021.07.033

---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

Will new PE guidelines redefine risk and therapy in pulmonary embolism (PE) care? In this episode of the BackTable podcast, host Dr. Michael Barraza is joined by interventional cardiologist Dr. Jay Giri and emergency physician Dr. Trevor Cummings to break down the latest changes in PE management. They discuss how multidisciplinary pulmonary embolism response teams (PERT) are implementing these guidelines at their institutions, the introduction of a more nuanced A-E risk stratification system, and the challenges of enrolling experienced centers into clinical trials as device innovation accelerates.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by

Stryker Peripheral Vascular, formerly Inari Medical
https://www.inarimedical.com/flowtriever-system

---

Timestamps

00:00 - Introduction
01:24 - Building a PERT Team
04:59 - Trials Shaping PE Care
10:20 - Why New Guidelines Now
14:06 - New Risk Categories Explained
19:51 - Applying Guidelines Locally
23:34 - What Is C1 Risk
27:52 - New D Category Explained
30:33 - Evidence for Aggressive Therapy
33:31 - How PERT Teams Communicate
38:22 - Upcoming PE Trials Pipeline
43:42 - Program Growth and High Risk Trials
45:46 - Closing Remarks

---

More about this episode

The conversation highlights the growth of catheter-directed lysis and mechanical thrombectomy, the rationale and practical impact of the new Category D for incipient cardiopulmonary failure (including normotensive shock), and the incorporation of PESI, sPESI, and Hestia for risk assessment. Additional topics include decision-making for low-risk patients, lactate and biomarkers for identifying higher-risk cases, communication strategies within PERT teams, AI-enabled risk stratification, and a preview of upcoming trials (PEITHO, PRAGUE-26, PEERLESS-2, PE-TRACT, and PERSEVERE) that are set to further transform PE care.

---

Resources

Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association
https://pubmed.ncbi.nlm.nih.gov/21422387/

Surgical Management and Mechanical Circulatory Support in High-Risk Pulmonary Embolisms: Historical Context, Current Status, and Future Directions: A Scientific Statement From the American Heart Association
https://pubmed.ncbi.nlm.nih.gov/36688837/

Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association
https://pubmed.ncbi.nlm.nih.gov/31585051/

Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism
https://pubmed.ncbi.nlm.nih.gov/41910345/

PEERLESS II: A Randomized Controlled Trial of Large-Bore Thrombectomy Versus Anticoagulation in Intermediate-Risk Pulmonary Embolism
https://pubmed.ncbi.nlm.nih.gov/39132600/

Rationale and design of the PE-TRACT trial: A multicenter randomized trial to evaluate catheter-directed therapy for the treatment of intermediate-risk pulmonary embolism
https://pubmed.ncbi.nlm.nih.gov/39638275/

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial
https://pubmed.ncbi.nlm.nih.gov/34560806/

Design and rationale of the PERSEVERE study: a randomized controlled trial of large-bore mechanical thrombectomy versus the standard of care for high-risk pulmonary embolism
https://pubmed.ncbi.nlm.nih.gov/41453591/

Design and rationale of PRAGUE-26: a multicentre, randomised trial of catheter-directed thrombolysis for intermediate-high risk acute pulmonary embolism
https://pubmed.ncbi.nlm.nih.gov/40464677/

---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

How can targeted liver radiation unlock surgical or transplant options for tough hepatocellular carcinoma (HCC) cases? In this episode of BackTable 2026 HCC Creator Weekend™ host Dr. Kavi Krishnasamy is joined by interventional radiologists Dr. Beau Toskich and Dr. Chris Malone to explore how downstaging and radiation lobectomy with Y-90 are creating new surgical and transplant opportunities for patients with limited future liver remnants. They discuss Y-90’s role as a “test of time” for tumor biology, strategies to prevent post-hepatectomy liver failure, and the ongoing challenge of recurrence even after R0 resection in cirrhotic livers.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by an educational grant from Sirtex and Boston Scientific.

---

Timestamps

00:00 - Introduction
01:31 - Rad Lobectomy Goals and Case Discussion
06:09 - Selective vs Lobar Dosing
07:51 - PVE Versus Y90
09:35 - Downstaging to Transplant
13:03 - Patient Selection Factors
19:22 - Radseg vs. Lobar Strategy
22:12 - Percent Liver Treated Debate
26:38 - Particle Density and Catheter Bias
28:04 - Downstaging Evidence MERIT LT
36:20 - Operating After Y90
41:25 - Hypertrophy Timing and Readiness
43:03 - Wrap Up

---

More about this episode

The discussion features a case of massive right-lobe HCC in a non-cirrhotic patient, with stepwise Y-90 dosing and selective retreatment leading to complete response and marked liver hypertrophy. The doctors compare radiation lobectomy with portal vein embolization (PVE), explore dosimetry advances from studies like DOSISPHERE and MERITS-LT, and stress the importance of careful mapping and patient selection. Additional topics include the pros and cons of different downstaging methods, functional imaging to assess risk, the impact of lab values and portal hypertension, and the practicalities of timing surgery after Y-90.

---

Resources

Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial
https://jnm.snmjournals.org/content/early/2024/01/10/jnumed.123.266211

Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium
https://pubmed.ncbi.nlm.nih.gov/37532179/

---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

When hemodialysis-dependent patients exhaust all conventional venous access options, how do IRs navigate complex central occlusions to provide a lifeline? In this episode of the BackTable Podcast, Dr. Gian Paolo Zamboni of Clínica Alemana in Santiago, Chile joins guest host Dr. Neil Jain to discuss workup protocols and advanced technical algorithms for complex central venous recanalization cases.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by

RADPAD® Radiation Protection
https://www.radpad.com/

---

Timestamps

00:00 - Introduction
03:06 - IR Practice and Referrals in Santiago
07:19 - Pre-Procedure Workup
15:06 - Standard Recanalization Techniques
20:14 - Dual-Access Sharp Recanalization
24:43 - Needle Maneuvers and Alternatives
29:32 - Predilation, IVUS, and Stent Sizing
37:42 - Transhepatic Technique and Indications
45:45 - Tract Closure, Anticoagulation, and Follow-up
50:03 - Advice and Closing Remarks

---

More about this episode

The physicians review the critical role of pre-procedural planning, emphasizing the necessity of thorough workup with CT venography to accurately assess remaining vascular capital. Dr. Zamboni shares how his group addresses severe central venous occlusions, outlining a structured, stepwise approach that begins with standard maneuvers and progresses to sharp recanalization techniques before opting for dual-access approaches. He outlines critical safety measures, highlighting the importance of performing intraprocedural cardiac ultrasound, pre-dilating with caution, and keeping covered stents on the shelf to prevent fatal cardiac tamponade. For patients who lack viable conventional iliofemoral and IVC access, Dr. Zamboni shares an advanced jugular-to-transhepatic strategy, walking through the steps and nuances of creating a reliable working route, optimizing inflow, and managing post-procedure anticoagulation. Finally, Dr. Zamboni offers invaluable advice for IRs on mastering foundational techniques before tackling advanced cases and building strong, collaborative relationships with referring providers.

---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

What does it really take to run a high-volume Y-90 program that is efficient, scalable, and patient-centered? In this episode of BackTable 2026 HCC Creator Weekend™, host Dr. Zach Berman is joined by Drs. Nima Kokabi and Kirema Garcia-Reyes to break down the systems, workflows, and strategies that drive successful radioembolization centers. The conversation focuses on overcoming referral and insurance delays, implementing multidisciplinary clinics, and using tools like single-session Y-90 and routine post-treatment dosimetry to reduce treatment times and improve outcomes.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by an educational grant from Sirtex and Boston Scientific.

---

Timestamps

00:00 - Introduction
04:46 - Multidisciplinary Model on Radioembolization
08:39 - Referral Pathways and Embolization Preferences
13:18 - Y-90 Follow Up and Imaging
15:51 - Procedure Preparation and Involvement
18:00 - Dosimetry Planning and Software ROI
22:59 - Analyzing Outcomes and Quality Control
26:47 - Various Ways to Expedite Treatments
34:04 - Wrap Up and Credits

---

More about this episode

The doctors discuss the importance of robust internal systems for patient selection, integration of dosimetry planning, and standardized follow-up protocols.They share insights on procedural workflows, including best practices for dosimetry ownership and equipment setup, and highlight the growing role of post-Y-90 dosimetry as both a quality control measure and a billable service. The episode also explores the order-map-treat paradigm, the impact of multidisciplinary tumor boards and clinics, and how single-session strategies are reshaping HCC care by cutting delays, reducing costs, and enhancing the patient experience.

---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

Routine doesn’t mean risk-free. What should be considered before, during, and after inferior vena cava (IVC) filter placement? In this episode of the BackTable Podcast, interventional radiologist Dr. Daniel O’Neal (Ohio State University) joins guest host Dr. Jessica Yoon to walk through the workup protocols, technical considerations, and multidisciplinary approaches required for placing and following up on IVC filters.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by

RADPAD® Radiation Protection
https://www.radpad.com/

---

Timestamps

00:00 - Introduction
02:10 - IVC Filter Basics
07:37 - Workup and Contraindications
12:18 - Pre-Procedural Imaging and Timing
14:35 - Procedural Technique
18:53 - Cavagram and Variant Anatomy
23:18 - Filter Positioning and Deployment
30:02 - IVC Filter Complications
33:58 - Post-Placement Follow-Up
39:14 - Final Thoughts and Closing Remarks

---

More about this episode

The physicians review the key indications for the procedure, highlighting evidence-based patient selection and emphasizing the need for interventional radiologists to critically assess the clinical workup rather than function merely as technicians. They discuss how a comprehensive pre-procedural workup relies on cross-sectional imaging to identify access obstacles and to plan for adequate filter placement in cases of variant anatomy. Dr. O’Neal also shares technical tips from the suite, including deployment mechanics, positioning considerations, and strategies for preventing common complications. The conversation concludes with the IR’s ongoing responsibility to ensure a robust, multidisciplinary follow-up system with referring specialties, outlining potential strategies to ensure these devices are safely retrieved in a timely manner when no longer indicated.

---

BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app